One of the main immunotherapeutic platforms consists of viral oncolytic therapy (23–26), which has the dual effect of i) direct killing of tumor (glioblastoma) cells and ii) the dying cells release neoantigens that can attract APCs and, in turn, activate CD4+ and CD8+ T cells. Here, CD8A is linked to glioblastoma.